Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 7/20 | 0.61 |
| ▸ | NPY2R | P49146 | 3/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447991 | 0.94 | LSS (0.70) | LSSNPY2RMGLLGAASMN1; SMN2 | |
| SCHEMBL6446588 | 0.91 | LSS (0.55) | LSSNPY2RMGLLGAASMN1; SMN2 | |
| SCHEMBL6447937 | 0.90 | LSS (0.51) | LSSNPY2RMGLLGAASMN1; SMN2 | |
| SCHEMBL6448159 | 0.85 | LSS (0.52) | LSSMGLLSMN1; SMN2 | |
| SCHEMBL6447566 | 0.84 | LSS (0.61) | LSSNPY2RMGLLGAATRPA1 | |
| SCHEMBL4803926 | 0.82 | LSS (0.89) | LSSSMN1; SMN2L3MBTL1 | |
| SCHEMBL4803931 | 0.82 | LSS (0.89) | LSSSMN1; SMN2L3MBTL1 | |
| SCHEMBL6449787 | 0.81 | LSS (0.62) | LSSNPY2RGAA | |
| SCHEMBL6449189 | 0.80 | LSS (0.70) | LSSNPY2RMGLLGAATRPA1 | |
| SCHEMBL7142436 | 0.80 | LSS (0.46) | LSSNPY2RMGLLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964974-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | LSS 2/4885NPY2R 1799/4885MGLL 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.